RE:RE:volatility and nervousnessNeurocrine Biosciences SP looks nice following April 11th 2017 approval of Ingrezza. The one early down tick seems to follow bad news on another trial for a different condition.
Went from$40 to $55 on approval. Dropped back to $40 on other bad news but now at $90.
CandideV007 wrote: I agree that both stories are totaly different... Egrifta is not a life saving drug and is a pain in the a** to inject. That's why I was asking you guys to show how different biotech stocks performed after FDA approval of a similar drug (ie monoclonal antibodies).
I got one that suggest that my prediction is wrong.
Alexion Solaris: - first drug for the company
- not life saving, but a massive market
- First approved on March 16th 2007, the shares took +8% that day.
- And after that, the stock kept climbing the chart and doubled in value by the end of the year.
- See the
chartby yourself.
You guys might make me change my decision... I will consider selling only half of my position.